Preliminary results from phase II study of combination treatment with HF10, a replication competent HSV-1 oncolytic virus, and ipilimumab in patients with stage Mb, Inc, or IV unresectable or metastatic melanoma.

被引：8
|
作者：
Andtbacka, Robert Hans Ingemar
Ross, Merrick I.
Agarwala, Sanjiv S.
Taylor, Matthew H.
Vetto, John T.
Neves, Rogerio Izar
Daud, Adil
Khong, Hung T.
Ungerleider, Richard S.
Boran, Aislyn
Tanaka, Maki
Grossmann, Kenneth F.
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] St Lukes Med Ctr, Easton, PA USA
[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[5] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[6] Penn State Hershey Canc Inst, Hershey, PA USA
[7] UC San Francisco, San Francisco, CA USA
[8] Theradex, Princeton, NJ USA
[9] Takara Bio Inc, Otsu, Shiga, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.9543
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9543
引用
收藏
页数：2
相关论文
共 7 条
  • [1] Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.
    Andtbacka, Robert Hans Ingemar
    Ross, Merrick I.
    Agarwala, Sanjiv S.
    Taylor, Matthew H.
    Vetto, John T.
    Neves, Rogerio Izar
    Daud, Adil
    Khong, Hung T.
    Ungerleider, Richard S.
    Tanaka, Maki
    Grossmann, Kenneth F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Tumor response from phase II study of combination treatment with intratumoral HF10, a replicationcompetent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melanoma
    Andtbacka, R.
    Ross, M.
    Agarwala, S. S.
    Taylor, M.
    Vetto, J.
    Neves, R. I.
    Daud, A.
    Khong, H.
    Ungerleider, R. S.
    Welden, S.
    Tanaka, M.
    Grossmann, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma
    Andtbacka, Robert Hans Ingemar
    Ross, Merrick I.
    Agarwala, Sanjiv S.
    Taylor, Matthew H.
    Vetto, John T.
    Neves, Rogerio Izar
    Daud, Adil
    Khong, Hung T.
    Ungerleider, Richard S.
    Tanaka, Maki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Topline results from phase II of combination treatment with canerpaturev (HF10), an oncolytic viral immunotherapy, and ipilimumab in patients with unresectable or metastatic melanoma after anti-PD-1 therapy
    Isei, T.
    Yokota, K.
    Uhara, H.
    Fujisawa, Y.
    Takenouchi, T.
    Kiyohara, Y.
    Uchi, H.
    Saruta, H.
    Ihn, H.
    Inozume, T.
    Watanabe, D.
    Takahashi, A.
    Fukushima, S.
    Tanaka, M.
    Yamazaki, N.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Final results from phase II of combination with canerpaturev (formerly HF10), an oncolytic viral immunotherapy, and ipilimumab in unresectable or metastatic melanoma in second-or later line treatment
    Yokota, K.
    Isei, T.
    Uhara, H.
    Fujisawa, Y.
    Takenouchi, T.
    Kiyohara, Y.
    Uchi, H.
    Saruta, H.
    Ihn, H.
    Inozume, T.
    Watanabe, D.
    Takahashi, A.
    Fukushima, S.
    Tanaka, M.
    Yamazaki, N.
    ANNALS OF ONCOLOGY, 2019, 30 : 557 - 557
  • [6] One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)
    Jamal, Rahima
    Van Kempen, Leon
    Thebault, Pamela
    Belanger, Karl
    Friedmann, Jennifer Elisabeth
    Ayoub, Jean-Pierre M.
    Cocolakis, Eftihia
    Kazemi, Shirin
    Dionne, Jeanne
    Lambert, Caroline
    Le, H. B.
    Grange, Cecile
    Cailhier, Jean-Francois
    Spatz, Alan
    Lapointe, Rejean
    Miller, Wilson H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB-IV melanoma.
    Chesney, Jason Alan
    Puzanov, Igor
    Ross, Merrick I.
    Collichio, Frances A.
    Milhem, Mohammed M.
    Chen, Lisa
    Kim, Jenny J.
    Garbe, Claus
    Hauschild, Axel
    Andtbacka, Robert Hans Ingemar
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
1